Talvey Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The talvey market research report is one of a series of new reports that provides talvey market statistics, including talvey industry global market size, regional shares, competitors with a talvey market share, detailed talvey market segments, market trends and opportunities, and any further data you may need to thrive in the talvey industry. This talvey market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The growth in the forecast period can be attributed to rising prevalence of autoimmune diseases, the aging population, increasing healthcare expenditure, focus on personalized medicine, government support and incentives. Major trends in the forecast period include focus on bioavailability improvements, combination therapy, demand for targeted therapies, demand for non-invasive treatments, and innovation in drug formulations.

The growing prevalence of hemophilia is expected to drive the growth of the NovoSeven and NovoSeven RT market. Hemophilia is a rare genetic bleeding disorder caused by a deficiency or absence of specific clotting factors in the blood, impairing the body’s ability to form proper blood clots and leading to prolonged or spontaneous bleeding, especially after injuries or surgeries. The rise in hemophilia cases is attributed to factors such as improved diagnosis, better management, increasing life expectancy, and population growth. NovoSeven and NovoSeven RT are effective treatments for hemophilia, providing recombinant activated factor VII therapy that helps control and prevent bleeding episodes, particularly for patients with inhibitors to standard clotting factor therapies. This ensures better management of the condition. For example, in November 2023, the National Institutes of Health reported that in 2022, 10,276 people with hemophilia from 87 centers across 40 countries were enrolled, with 49% having severe hemophilia, 99% being male, and 85% having hemophilia A. Thus, the growing prevalence of hemophilia is driving market growth.

The increasing healthcare expenditure is expected to boost the growth of the NovoSeven and NovoSeven RT market. Healthcare expenditure refers to the total financial resources spent by individuals, governments, or organizations on medical goods, services, public health initiatives, and related activities to improve health. The increase in healthcare spending is due to factors such as aging populations, the rise in chronic diseases, and the growing demand for better healthcare infrastructure. NovoSeven and NovoSeven RT contribute to healthcare expenditure by providing effective treatments for severe bleeding conditions, such as hemophilia and postpartum hemorrhage. These treatments help reduce the need for costly emergency interventions, prolonged hospital stays, and additional procedures, improving the cost-efficiency of managing critical health conditions. For instance, in June 2024, Health Affairs projected that U.S. healthcare spending would grow from 17.3% of GDP in 2022 to 19.7% by 2032, with a 7.5% increase in national health expenditures expected for 2023. Therefore, the increasing healthcare expenditure will drive market growth.

A key trend in the NovoSeven and NovoSeven RT market is the focus on developing innovative therapeutic applications, such as the treatment of severe postpartum hemorrhage (PPH), to address unmet medical needs and expand treatment options. Severe postpartum hemorrhage refers to excessive bleeding after childbirth, which can pose significant risks to maternal health. In April 2022, Novo Nordisk announced that the European Medicines Agency had approved NovoSeven for the treatment of severe postpartum hemorrhage. This treatment offers a targeted approach to controlling life-threatening bleeding in postpartum patients, especially those who do not respond to conventional therapies. The approval highlights the ability of NovoSeven to rapidly enhance blood clotting, providing a crucial solution for managing severe hemorrhage where traditional uterotonics and surgical interventions may be ineffective.

The key company operating in the talvey market is Johnson & Johnson.

North America was the largest region in the talvey market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in talvey report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the talvey market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Talvey is a biosimilar medication designed to treat various autoimmune diseases by targeting and inhibiting the activity of integrins, which are proteins involved in inflammation and immune cell movement. It is commonly prescribed for conditions such as multiple sclerosis (MS) and Crohn's disease, where it helps reduce inflammation, prevent relapses, and improve patient outcomes.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main formulations of Talvey include a 3 mg per 1.5 ml version and a 40 mg per ml version. The 3 mg per 1.5 ml formulation refers to a specific dosage of Talvey where each 1.5 ml contains 3 mg of the active ingredient. This version is typically used for the treatment of relapsed or refractory multiple myeloma as a monotherapy. It is distributed through various channels such as hospital pharmacies, specialty pharmacies, and online pharmacies, and is used by both adults and geriatric patients.

The talvey market consists of sales of biosimilars, monoclonal antibodies, corticosteroids, and immunosuppressants. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.